Virology Flashcards
2 theories of how viruses fit into the tree of life?
- RNA world theory: life arose with the viruses
- Reductionist theory: viruses came after cellular life, they are reduced versions of cellular organisms
* mimiviruses and megaviruses may be the missing link
What are Ribozymes?
- RNAs that can catalyze specific reactions (similar to enzymes)
- ribozymes (produced in lab) can catalyze their own synthesis
- natural fans: cleave RNA, viral replication, tRNA biosynthesis
Examples of DNA viruses?
- herpes, smallpox, mimivirus
DNA -> RNA -> protein
Examples of RNA viruses?
- Rhino, influenza, SARS
RNA-> protein
Examples of Retroviruses?
- HIV
RNA -> DNA (through reverse transcriptase) -> RNA -> protein
Pros and cons of a DNA virus
pros: lower mutation rate, more stable (can carry more genes), no dsRNA phase
cons: lower mutation rate, slower replication
Pros and cons of RNA virus
pros: fast replication rate, high mutation rate
cons: high mutation rate, limited sequence space (less stable), dsRNA phase, degrades faster, humans don’t have dsRNA (easy to identify)
What happens frequently in reverse transcriptase?
- 1 mutation per virus, much more common in retrovirus
What are some challenges in developing HIV vaccines?
- high mutation rate
- integration into host genome
- infects immune privileged region of host
- targets immune system
- multiple serotypes
- costs and time involved in development
- vaccine safety concerns
What is the diversity in HIV strains
- 25-30% in circulating HIV strains
- mutation rate is - 1 base change per genome
What effects can a mutation have on a virus?
- not all mutations are advantageous: some hinder the virus, some prevent virus replication, and some are silent ( have no effect)
- Some allow a competitive advantage, and some allow escape from antiviral drugs
antiretroviral drug classes
- reverse transcriptase inhibitors (NRTIs)
- Fusion/entry inhibitors
- Integrase inhibitors
- Protease inhibitors
Difference b/t nucleosides and nucleotides?
- nucleosides: sugar+ base
3 phosphorylation events required for activity
-nucleotide: sugar+base+phosphate, 2 phosphorylation events required for activity
Nucleoside analogs??
prevent adding of next nucleoside on to the chain looks like nucleoside but doesn’t have site to bind to next nucleoside so it is a chain terminator
3TC (Epivir/Iamivudine)
- FDA approved 1995
- reverse transcriptase inhibitor
- nucleoside analog: mimics cytidine -> acts as a chain terminator
DLV (Rescriptor/delavirdine)
- FDA approved 1997
- Reverse transcriptase inhibitor (non-nucleoside)
- binds RT catalytic site, blocking polymerase fxn
Reverse transcriptase mutations?
- only takes 1 or 2 mutations of virus to make reverse transcriptase drugs ineffective
DRV (darunavir/Prezista)
- FDA approved 2006
protease inhibitor: binds the active site preventing the processing of viral protein precursors - compete with the natural substrate
EVG (Elvitegravir)
- FDA approved 2014
- Allosteric integrase inhibitor (prevents functional multimers from forming (dimers of dimers= tetramer)
MVC (Selzentry/maraviroc)
- FDA approved 2007
- entry inhibitor (receptor antagonist)
drug binds receptor (CCR5), preventing HIV from binding - mutant bind receptor in a different conformation
T20 (Fuzeon/entuvirtide)
- FDA approved 2003
- HIV fusion inhibitor
- mimics viral protein to displace it in the fusion complex (binds p41 and prevents formation of the entry pore)
Vacc-4x
therapeutic vaccine
in clinical trials 9phase 2)
peptide vaccine -> dropped viral load but didn’t slow CD4 T cell decline
SB-728T gene therapy
in phase 1/2 trials
modifies a CD4 T cell CCR5 receptor, making it non-functional, prevents HIV entry
- harvest patient T cells, make mutation and replicate, and put back into pt
- this mutation occurs naturally and confers HIV resistance
- expensive and time consuming
Interleukin
IL-7: trial abandoned b/c IL-7 increased the number of CD4+ T cells but that increased viral load too
IL-2: increased number of CD4+ T cells but didn’t significantly decrease clinical events or death, even when combined with antiretrovirals